An exploratory assessment of the effect of bazedoxifene on glucose metabolism and bone quality in postmenopausal women with type 2 diabetes.

Not Applicable

Completed

• Conditions: Type 2 diabetes mellitus

• Registration Number: JPRN-UMIN000010074
• Lead Sponsor: Yokohama City University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-02-20
• Study Completion: 2013-12-31
• Last Update Posted: 2023-10-17

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: Female
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1.Past history of bone fractures related to non-traumatic accident. 2.Current use of pioglitazone (regardless of treatment duration). 3.Current use of steroid hormones (regardless of treatment duration). 4.The patients with the thyroid function abnormality for which treatment is needed. 5.Current use of other medications for osteoporosis: Vitamin D: within 12 weeks after the suspension of administration. Vitamin K2:within 12 weeks after the suspension of administration. Bisphosphonates:within 24 weeks after the suspension of administration. The others SERM(raloxifene):within 24 weeks after the suspension of administration. PTH:within 24 weeks after the suspension of administration. 6.Past history of deep vein thrombosis. 7.Cancer bearing patients. 8.Patients determined to be inappropriate by physician.

Study & Design

• Study Type: Interventional
• Study Design: Not specified